MabThera/Rituxan

Roche keeps Venclexta train rolling with new leukaemia filing

population was expanded after the regulator okayed its use alongside Roche’s Rituxan (rituximab) for all relapsed/refractory CLL patients based on the MURANO trial results.

CTI slumps as Servier-partnered lymphoma drug fails

The PIX306 trial paired Pixuvri (pixantrone) – already sold in some European markets as a monotherapy for hard-to-treat NHL – with Roche’s MabThera (rituximab) and compared it to MabThera plus

AbbVie, Roche get FDA OK for broader use of Venclexta

now also be used in patients without that mutation, both alone and in combination with Rituxan. ... A similar marketing application is under review by the EMA. In MURANO, giving first-in-class BCL-2-targeting drug Venclexta (venetoclax) with anti-CD20

Roche’s MabThera ends drug drought for serious skin disease

Roche’s ageing blockbuster MabThera has picked up a new approval in life-threatening skin disorder pemphigus vulgaris, becoming the first new treatment for the disease in six decades. ... MabThera (rituximab) – an anti-CD20 antibody known as Rituxan

Ocrevus helps Roche stave off biosimilar threat

The third of the big three - Mabthera/Rituxan (rituximab) - did not fare as well as its peers however, with sales down 8% to CHF 1.7bn overall and plummeting 44% in

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]